ISTA Pharmaceuticals has acquired rights to two of Senju Pharmaceuticals, Co.'s drug candidates for the treatment of glaucoma, a chronic disease that, according to the Glaucoma Research Foundation, is the second leading cause of blindness. Senju's lead candidates licensed by ISTA are iganidipine, a calcium channel blocker, and a new formulation of latanoprost, a prostaglandin.
ISTA paid Senju an approximated $8 million in upront, developmental and milestone fees, plus royalties on future sales. ISTA will be resposible for the development of the two drug candidates for the North American market, including the applications for regulatory approvals, manufacturing and marketing.
More details of the licensing deal from ISTA's press release.
Comment Preview